Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PKLR | P30613 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376376 | 1.00 | KDM4E (0.46) | KDM4EEPHX2MAPTALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL2249026 | 0.98 | KDM4E (0.45) | KDM4EEPHX2MAPTALDH1A1KMT2A | |
| SCHEMBL15893901 | 0.92 | KDM4E (0.50) | KDM4EEPHX2MAPTALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL2595097 | 0.90 | KDM4E (0.48) | KDM4EEPHX2MAPTALDH1A1KMT2A | |
| SCHEMBL17582292 | 0.86 | KDM4E (0.39) | KDM4EEPHX2MAPTALDH1A1KMT2A | |
| SCHEMBL30135255 | 0.85 | KDM4E (0.42) | KDM4EEPHX2MAPTALDH1A1KMT2A | |
| SCHEMBL13100462 | 0.82 | — | — | |
| SCHEMBL5405216 | 0.77 | EPHX2 (0.44) | KDM4EEPHX2MAPTALDH1A1KMT2A | |
| SCHEMBL16022965 | 0.77 | EPHX2 (0.44) | EPHX2ALDH1A1KMT2APKMPOLB | |
| SCHEMBL28959739 | 0.76 | KDM4E (0.46) | KDM4EMAPTALDH1A1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| EP-3044210-A2 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | Cortendo AB (publ) (US) | 2016-07-20 | — | — | EP | claimed |
| EP-2300469-A2 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-03-30 | — | — | EP | claimed |
| WO-2009140128-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-11-19 | — | — | WO | claimed |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | PROSETTA BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250214954-A1 | METHODS OF TREATING HIV USING TRITERPENE DERIVATIVES | HETERO LABS LIMITED (IN) | 2025-07-03 | — | — | US | disclosed |
| US-12275727-B2 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | 280 BIO, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-12275712-B2 | Triterpene derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2025-04-15 | — | — | US | disclosed |
| EP-4488275-A1 | COMPOUND CONTAINING FIVE-MEMBERED HETEROAROMATIC RING STRUCTURE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Yingli Pharmaceutical Co., Ltd (CN) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024254990-A1 | COMPOUND HAVING HETEROAROMATIC RING STRUCTURE, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海璎黎药业有限公司 | 2024-12-19 | — | — | WO | disclosed |
| WO-2007064883-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC. (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1638942-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-29 | — | — | EP | disclosed |
| US-6861432-B2 | Piperazine derivatives that destabilize androgen receptors | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-01 | — | — | US | disclosed |
| WO-2005003097-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| US-20040259884-A1 | Cis-imidazolines | HALEY GREGORY JAY (US) | 2004-12-23 | — | — | US | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
| US-20040009969-A1 | Piperazine derivatives that destabilize androgen receptors | SCHERING AG (DE) | 2004-01-15 | — | — | US | disclosed |
| WO-2003043983-A1 | PIPERAZINE DERIVATIVES DESTABILISING ANDROGEN RECEPTORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259884-A1 | Cis-imidazolines | TP53, MDM2, TP53BP1 | KDM4E 3892/4885EPHX2 4375/4885MAPT 2511/4885 |
| US-12275727-B2 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | PARG, CYP3A5, CYP11B1 | KDM4E 1465/4885EPHX2 315/4885MAPT 1695/4885 |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | KDM4E 2746/4885EPHX2 2949/4885MAPT 4148/4885 |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | NCOR1, HAVCR2, NR3C1 | KDM4E 4577/4885EPHX2 2254/4885MAPT 3761/4885 |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | KDM4E 3361/4885EPHX2 1309/4885MAPT 2827/4885 |
| US-12275712-B2 | Triterpene derivatives as HIV inhibitors | CCR5, CYP51A1, CYP4A11 | KDM4E 1058/4885EPHX2 1888/4885MAPT 1686/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | KDM4E 2746/4885EPHX2 2949/4885MAPT 4148/4885 |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | MAVS, SARS1, ZC3HAV1 | KDM4E 4045/4885EPHX2 2862/4885MAPT 3295/4885 |
| US-20040009969-A1 | Piperazine derivatives that destabilize androgen receptors | AR, FSHR, GNRHR | KDM4E 1947/4885EPHX2 3959/4885MAPT 4808/4885 |
| US-20250214954-A1 | METHODS OF TREATING HIV USING TRITERPENE DERIVATIVES | CCR5, HSD17B7, CYP51A1 | KDM4E 1708/4885EPHX2 1776/4885MAPT 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.